Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ethyl-EPA · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Ethyl-EPA (Miraxion™) | DRUG | - |
Inclusion Criteria: * Clinical features of Huntington's disease (HD) and confirmatory family history of HD, and/or CAG repeat expansion greater than or equal to 36 * Ambulatory, not requiring skilled nursing care (total functional capacity \[TFC\] greater than or equal to 7) * Chorea score of at le...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Votoplam |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE3 | Valbenazine |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE1 | ALN-HTT02 |
| uniQure N.V. | QURE | 2 | PHASE1 | intra-striatal rAAV5-miHTT |
| Sarepta Therapeutics, Inc. | SRPT | 1 | PHASE1 | SRP-1005 |
Ethyl-EPA is an investigational small molecule being studied for the treatment of Huntington Disease. It was evaluated in the TREND-HD clinical trial, which enrolled 300 patients with mild to moderate Huntington Disease. The trial was a Phase 3, randomized, double-blind study conducted in the United States and Canada.
Ethyl-EPA is being developed by Amarin Corporation plc, a biopharmaceutical company listed on the stock exchange under the ticker AMRN. The company sponsored the Phase 3 clinical trial of Ethyl-EPA for Huntington Disease.
Ethyl-EPA has completed a Phase 3 clinical trial for Huntington Disease. The trial, known as TREND-HD, was a randomized, double-blind study that enrolled 300 participants. As an investigational drug, Ethyl-EPA is still in clinical development and has not been approved by regulatory authorities.
Ethyl-EPA was studied in the TREND-HD trial, registered as NCT00146211. This Phase 3 trial evaluated Ethyl-EPA in treating mild to moderate Huntington Disease. The study enrolled 300 participants aged 35 years and older in the United States and Canada, and it has been completed.
Yes, Ethyl-EPA is also known as Miraxion. The Phase 3 clinical trial for Huntington Disease, TREND-HD, was titled 'A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease.' This alternative name may be used in clinical and research contexts.